Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Lymphoid 1CNS 1

Conditions

Solitary Fibrous Tumors 1Sarcoma 1Neoplasm Metastasis 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Granuloma, Plasma Cell 1Glioma 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Cyclophosphamide 16Filgrastim 15Etoposide 10Carboplatin 10Peripheral Blood Stem Cell Transplantation 8Melphalan 8Magnetic Resonance Spectroscopy 7Granulocyte Colony-Stimulating Factor 7Busulfan 7Thiotepa 6Temozolomide 6Radiotherapy 6Ifosfamide 6etoposide phosphate 5X-Rays 5Topotecan 5Phantoms, Imaging 5Doxorubicin 5Cisplatin 5Vincristine 4Specimen Handling 4Nuclear Medicine Department, Hospital 4Mesna 4selpercatinib 3sargramostim 3pembrolizumab 3palbociclib 3aldesleukin 3Sirolimus 3Radiosurgery 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × Capsules × CNS × Clear all
NCT04094610 2025-11-19

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
75 enrolled
CNSLymphoidPlasma cellSarcoma

Glioblastoma, Glioma, Granuloma, Plasma Cell, Lymphoma, Neoplasm Metastasis, Sarcoma, Lymphoma, Large-Cell, Anaplastic, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡